[May 21, 2015]

Research and Markets: Global Glomerulonephritis Pipeline Report 2015 - 12 Companies & 13 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/sqpgb5/glomerulonephritis) has announced the addition of the "Glomerulonephritis - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.

The report enhances decision making apabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Adienne Pharma & Biotech
• Alexion Pharmaceuticals, Inc.
• Avexxin AS
• Biogen Idec Inc.
• ChemoCentryx, Inc.
• FibroStatin SL
• GlaxoSmithKline plc
• Hansa Medical AB
• Mallinckrodt plc
• New Zealand Pharmaceuticals Limited
• Pharmalink AB
• Toray Industries, Inc.

Drug Profiles

• AVX (News - Alert)-235
• belimumab
• budesonide
• CCX-168
• corticotropin
• DEXM-74
• Drug to Inhibit GPBP for Glomerulonephritis and Cancer
• eculizumab
• Endoglycosidase of Streptococcus pyogenes
• Mubodina
• Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis
• rituximab
• Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis

For more information visit http://www.researchandmarkets.com/research/sqpgb5/glomerulonephritis

View source version on businesswire.com: http://www.businesswire.com/news/home/20150521005593/en/

[ Back To TMCnet.com's Homepage ]